Document is current
Any future updates will be listed below
-
Authors
Franklin, Matthew https://orcid.org/0000-0002-2774-9439
Fotheringham, James https://orcid.org/0000-0002-8980-2223
Taylor, Rod S. https://orcid.org/0000-0002-3043-6011
Powell, Philip A. https://orcid.org/0000-0003-1169-3431
Retat, Lise https://orcid.org/0000-0002-6689-3599
Chen, Jieling
Sanchez, Juan Jose Garcia https://orcid.org/0000-0001-6546-7769
Gamble, Amy https://orcid.org/0009-0002-0209-295X
Carter, Patrice https://orcid.org/0000-0003-3445-6754
-
Funding
Funding for this research was provided by:
AstraZeneca United States
- License Information
-
More Information
Article History
Received: 28 November 2025
Accepted: 10 May 2026
First Online: 1 June 2026
Declarations
Conflict of interest: MF, RST and PP declare no conflicts of interest. JF received consultancy funding to support the design and conduct of the systematic review, paid to his employer, and is Chair of NICE Technology Appraisal Committee C. JJGS, LR, JC and PGDF are employees and shareholders of AstraZeneca. AG and PC are, or were employees of HEOR Ltd, who are paid consultants to AstraZeneca in connection with the development of this manuscript.
Ethics approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Data availability: The data sets generated during and/or analysed during the current review are available from the corresponding author on reasonable request.
Author contributions: All authors contributed to the development of the study protocol. AG and PC conducted the screening, data extraction and synthesis of the SLR. All authors contributed to the interpretation of data, preparation and review of the manuscript, and gave approval of the final manuscript for publication.
